Mission Therapeutics to Present at Conferences in March – April 2016
CAMBRIDGE, UK – 31 March 2016 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that Anker Lundemose, Chief Executive Officer, Dr Xavier Jacq, VP Scientific Affairs, Dr Paul Wallace, Chief Business Officer and Dr Michael Koslowski, Chief Medical Officer & EVP Research & Development, are scheduled to attend the following events:
(1) Biotechs and the City Spring, 31 March 2016, London, UK
Dr Anker Lundemose, CEO, to present an overview of MISSION Therapeutics on Thursday, 31 March at 6.00pm GMT
Biotechs and the City events are organised by Biotech and Money and feature highly topical short presentations or a thematical 45 minute Panel Discussion from industry Executives.
(2) Mitochondrial dynamics – Keystone Symposia, 3- 7 April 2016, Colorado, USA
Dr Xavier Jacq, VP Scientific Affairs, to attend
This meeting will highlight the latest advances in diverse disciplines including neurology, aging, cancer research, autophagy, membrane morphogenesis, structural biology and bioenergetics. The programme groups the best senior and junior scientists in these disciplines to break down barriers between different fields of research and promote innovation. As the most important discoveries in mitochondrial dynamics lie ahead, the interactions at this meeting should play a key role in their advance.
(3) BIO – Europe Spring, 4-6 April 2016, Stockholm, Sweden
Dr Paul Wallace, Chief Business Officer, to attend
The premier springtime partnering conference which annually attracts an international “who’s who” from biotech, pharma and finance for three days of high calibre networking.
(4) AACR annual meeting 2016, 16 – 20 April 2016, New Orleans, Louisiana
Dr Xavier Jacq, VP Scientific Affairs, and Dr Michael Koslowski, Chief Medical Officer & EVP Research and Development, to attend
The AACR Annual Meeting will focus on “Delivering Cures Through Cancer Science” reinforces the inextricable link between research and advances in patient care. The theme will be evident throughout the meeting as the latest, most exciting discoveries are presented in every area of cancer research.
(5) BioTrinity, 25- 27 April 2016, London, UK
Dr Paul Wallace, Chief Business Officer, to attend
BioTrinity is the nexus of a booming life sciences innovation ecosystem and provides a unique platform for R&D, global pharma and investor companies across the life sciences industry to achieve their business objectives; to secure funding, seek acquisition and in-licensing deals and grow their network.
For further events, please visit the MISSION Therapeutics website.
For more information:
CONTACT:
MISSION Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel +44 1223 497199
Hume Brophy
Mary Clark, Eva Haas, Hollie Vile
Email: missiontherapeutics@humebrophy.com
Tel: +44 (0) 20 7862 6390
NOTES TO EDITORS:
About MISSION Therapeutics
MISSION Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and non-malignant disease. It has built a world-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.
DUBs are involved in multiple cellular processes, including DNA damage response and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease. Despite significant efforts within the pharmaceutical sector, there is a lack of DUB inhibitors in clinical development.
MISSION’s leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge. Professor Steve Jackson at Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge is the scientific founder of MISSION and is the Chief Scientific Officer of the Company.
MISSION Therapeutics has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. MISSION is based at the Babraham Research Campus, south of Cambridge.
